Replies to post #14769 on GTC Biotherapeutics (fka GTCB)

[floblu14]

>There should be enough information uncovered by the P2 clinicals to get a very solid idea of the efficacy of Atryn.<

Although GTC has had only one new patent application since March, this last one in August needs careful analysis -

Is GTC on to something that will increase survival in DIC patients?

>Recombinant human AT (ATryn(R); GTC Biotherapeutics, Framingham, MA) was used in this experiment<

>The methods and compositions provided can be used, for example, for the treatment or prophylaxis of sepsis, disseminated intravascular coagulation (DIC), peritonitis, ovarian cancer, or for any gastrointestinal injury or infection.<

>....intraabdominal administration of a high dose of rhAT by peritoneal lavage reduced intraabdominal coagulation activation and fibrin formation, without severe derangements in coagulation that could lead to serious bleeding complications, and concomitantly improved i bacterial clearance and inflammatory responses. This resulted in reduced inflammation and coagulation activation in the pulmonary compartment, and ultimately in survival.<

Anyone have the time to decipher this further? TIA

http://v3.espacenet.com/publicationDetails/description?CC=WO&NR=2008100258A1&KC=A1&FT=D&date=20080821&DB=EPODOC&locale=en_V3

[go seek]

"It seems a number of posters on this site have focused in on the upcoming decision of the FDA to approve Atryn as a sentinel event for GTC and one which would cause an immediate and long term dramatic rise in the PPS."

Are you prepared to predict the PPS of GTC after ATryn approval? A difficult - impossible task... we may be surprised by the upside (and we may be disappointed).

We agree; the AD indications, particularly DIC are the potential homeruns as per ATryn... but GTC must get to the plate first with the HD approval. That action will help open doors. i.e. If ATryn fails in the HD indication we won't be considering it in the US for DIC, CABG, et al.

We should not discount any clinical progress made by the company (and I know you are not) the FDA approval of ATryn, an ATryn partnership for Japan, a partnership for CD137 or partnerships for the FoB's, etc.

Best wishes JL...